Neurotech International’s NTI164 Shows Promising PK Study Results

Neurotech International ( (AU:NTI) ) has issued an update.

Neurotech International announced positive results from its human pharmacokinetic study of NTI164, a CBDA-rich formulation. The study confirmed rapid absorption, minimal THC exposure, and stable cannabinoid profiles, supporting NTI164’s safety and effectiveness for paediatric use. The findings bolster NTI164’s potential as a long-term treatment option and support its progression into future registration trials with the US FDA and Australian TGA, aiming to accelerate global access to this treatment.

More about Neurotech International

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on developing treatments for paediatric neurological disorders. The company is engaged in advancing its proprietary CBDA-rich formulation, NTI164, aimed at providing therapeutic solutions for children with neurological and inflammatory brain conditions.

Average Trading Volume: 778,532

Technical Sentiment Signal: Sell

Current Market Cap: A$22.04M

Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.